J&J Proposes $5.5 Billion Settlement to End US Talc Cancer Litigation

Key points

• J&J offered up to $5.5 billion to settle roughly 69,000 US talc-related cases, representing 99.75% of outstanding claims.
• The settlement requires the first payment of no more than $3 billion in 2027, with no further payments due before 2028.
• The agreement is contingent on acceptance by legal firms representing at least 95% of the remaining ovarian cancer claims.
• J&J maintains that talc is safe and does not cause cancer, citing a recent MDL court ruling that plaintiffs could not prove specific causation.
• The deal does not cover the UK, where a separate case involving over 7,000 claimants is currently being adjudicated by the High Court.

Background

Litigation over J&J’s talc products began around 2009, with the first major US verdict in 2016. The World Health Organization classified talc as probably carcinogenic in 2024. J&J stopped selling talc-based baby powder in the US in 2020 and globally in 2023, transitioning to cornstarch-based products. Our archive notes that oncologists have previously warned about cancer risks from asbestos contamination in talc deposits, while J&J has consistently denied these links.

How outlets are covering it

J&J’s litigation head, Erik Haas, characterized the claims as meritless and stated the company would have prevailed in further litigation, citing a recent MDL court order that plaintiffs failed to prove specific causation. In contrast, plaintiff lawyers welcomed the settlement as a fair resolution to a decade-long battle. BBC highlighted the financial scale of the deal, noting the $4.14 billion equivalent, while Yahoo Finance emphasized the strategic efficiency of ending the litigation after a favorable causation ruling. Al Jazeera noted the exclusion of the UK from the settlement, highlighting the ongoing risk from the largest product liability case in UK history.

Why it matters

The settlement resolves the vast majority of US talc-related litigation, providing financial certainty for J&J and compensation for claimants. However, the exclusion of the UK case, which involves over 7,000 claimants and alleges J&J knew of cancer risks, leaves significant legal exposure. The outcome also sets a precedent for product liability cases involving carcinogenic minerals, potentially influencing future litigation in other jurisdictions.

What to watch

The settlement must be approved by legal firms representing 95% of the remaining claims to become final. J&J expects to make the first payment of up to $3 billion in 2027. Meanwhile, the UK High Court will continue to adjudicate the separate case involving over 7,000 claimants, which alleges J&J concealed cancer risks. J&J has already halted global sales of talc-based baby powder and shifted to cornstarch-based products.